Description: Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for oncology and behavioral brain disorders. The company's lead product is SFX-01 that is in Phase II clinical trials for the treatment of metastatic breast cancer; and in Phase I clinical trials for the treatment of neurodevelopmental disorders and glioblastoma, as well as in preclinical stage for the treatment of rhabdomyosarcoma. In addition, it engages in the development of orexin 1 antagonist, which is in late preclinical stage targeting addiction and anxiety; and atypical dopamine transporter inhibitor (DAT), which is in late preclinical stage targeting fatigue and narcolepsy. The company was formerly known as Evgen Pharma plc and changed its name to Theracryf Plc in April 2024. Theracryf Plc was incorporated in 2014 and is headquartered in Nether Alderley, the United Kingdom.
Home Page: theracryf.com
TCF Technical Analysis
Alderley Park
Nether Alderley,
SK10 4TG
United Kingdom
Phone:
44 1625 315 090
Officers
| Name | Title |
|---|---|
| Dr. Huw Jones BSc, Ph.D. | CEO & Executive Director |
| Mr. Toni Haenninen | CFO & Director |
| Dr. Helen Kuhlman Ph.D. | Chief Business Officer |
| Dr. Glen Clack FFPM, M.D. | Chief Medical Officer |
Exchange: LSE
Country: GB : United Kingdom of Great Britain and Northern Ireland
Currency: Pence sterling (p)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.8454 |
| Price-to-Sales TTM: | 5.6957 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 9 |